PMC4620390_01
Visual analogue scale of pain. *: Wilcoxon signed-rank test of the before and after treatment values, p < 0.05; **: t-test of the before treatment and after one year of follow-up values, p < 0.05.
ECAM2015-263898.002.jpg
PMC4620390_01_ECAM2015-263898.002.jpg
fig2
The average VAS score for pain was significantly decreased from 9 (1.15) to 2.75 (2.22) (p < 0.01, Figure 2). The pain VAS score decreased significantly during the treatment from 7.88 (1.48) to 2.33 (1.37, p < 0.001), and it continued to improve over the one-year follow-up period (2.10 (1.98), p < 0.001, Figure 2).
Walking duration without pain. *: Wilcoxon signed-rank test of the before and after treatment values, p < 0.05; **: t-test of the before treatment and after one year of follow-up values, p < 0.05.
ECAM2015-263898.003.jpg
PMC4620390_01_ECAM2015-263898.003.jpg
fig3
The average walking duration without pain was also significantly improved from 5.5 (6.66) to 16.75 (13.00) minutes (p < 0.01, Figure 3). The walking duration without pain also showed significant improvement during the treatment (4.21 minutes (5.48) at the pretreatment and 16.00 (7.30) minutes at the posttreatment assessments), and it continued to improve after one year (20.25 (10.56), p < 0.001, Figure 3).